GMP compliance – Page 13

How to Justify Bracketing for Multiple Strength Pharmaceutical Products

Effective Approaches to Justify Bracketing in Multi-Strength Pharmaceutical Products In the world of pharmaceutical manufacturing, ensuring stability for multi-strength products through bracketing and matrixing can present numerous challenges. Misuse of…

Ongoing Stability Testing Frequency Errors and How to Prevent Them

Addressing Frequency Errors in Ongoing Stability Testing Programs In the pharmaceutical industry, ongoing stability program gaps can lead to significant regulatory compliance challenges and potential risks to product quality. These…

Why Matrixing Designs Fail When Strengths Are Not Truly Comparable

Understanding Failures in Matrixing Designs Due to Incomparable Strengths In the complex world of pharmaceutical stability studies, ensuring the reliability of results is paramount. A common issue arises when matrixing…

Common Failures in Selecting Batches for Ongoing Stability Programs

Tackling Common Failures in Batch Selection for Stability Programs The ongoing stability program (OSP) is a critical component of pharmaceutical quality assurance, ensuring that drug products remain effective and safe…

ICH Q1D Bracketing and Matrixing: Mistakes QA Must Prevent

Preventing Misuse of ICH Q1D Bracketing and Matrixing in Pharmaceutical Quality Assurance In the pharmaceutical industry, maintaining the integrity and reliability of stability studies is crucial. However, numerous cases of…

How to Design an Ongoing Stability Program for Commercial Products

Creating an Effective Ongoing Stability Program to Address Common Gaps Managing ongoing stability program gaps in pharmaceutical manufacturing is critical for ensuring product quality and regulatory compliance. A robust stability…

How Wrong Bracketing Assumptions Can Invalidate Stability Data

Understanding the Impact of Bracketing Assumptions on Stability Data Validity In pharmaceutical manufacturing, the integrity of stability data is paramount for ensuring product quality and compliance with regulatory standards. A…

Ongoing Stability Program Gaps That Lead to Regulatory Observations

Identifying and Addressing Gaps in Ongoing Stability Programs to Prevent Regulatory Issues Ongoing stability program gaps can pose significant regulatory risks in the pharmaceutical industry. When stability data is not…

Bracketing and Matrixing Misuse in Stability Studies: Common Regulatory Gaps

Addressing Bracketing and Matrixing Misuse in Stability Studies: Understanding Regulatory Gaps In pharmaceutical development, bracketing and matrixing are essential strategies to streamline stability studies, particularly when evaluating the stability of…

Tag: GMP compliance